For example, preclinical studies in lymphoma have shown that treatment with Flt3L, radiation and poly(ICLC) led to PD-L1 upregulation in both tumour cells and intratumoural DCs, and that the further addition of anti-PD-1 antibody led to improved local and systemic tumour control (258). Here, FLT3LG is linked to lymphoma.